{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:42:58Z","timestamp":1793400178136,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K19486"],"award-info":[{"award-number":["23K19486"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NIAMS","award":["AR041199"],"award-info":[{"award-number":["AR041199"]}]},{"name":"NIH\/NIDCR","award":["DE000704"],"award-info":[{"award-number":["DE000704"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1136\/ard-2023-224842","type":"journal-article","created":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T06:42:27Z","timestamp":1717310547000},"page":"1034-1047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sj\u00f6gren's disease"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct04496960","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04496960","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00001390","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02327884","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00001196","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-3554","authenticated-orcid":false,"given":"Sarthak","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas JF","family":"Pranzatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalie","family":"Dominick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyh-Ing","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Abed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Burbelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChangYu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Alevizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Khavandgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Pelayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Walitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4164-8837","authenticated-orcid":false,"given":"Sarfaraz","family":"Hasni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-0815","authenticated-orcid":false,"given":"Mariana J","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Magone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Chiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4961-018X","authenticated-orcid":false,"given":"Blake M","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224842_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102364","article-title":"Sj\u00f6gren's syndrome: old and new therapeutic targets","volume":"110","author":"Mavragani","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2023-224842_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167490","article-title":"Single-cell profiling reveals pathogenic role and differentiation trajectory of granzyme K+Cd8+ T cells in primary Sj\u00f6gren's syndrome","volume":"8","author":"Xu","year":"2023","journal-title":"JCI Insight"},{"key":"10.1136\/ard-2023-224842_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681941","article-title":"The transcriptome of paired major and minor salivary gland tissue in patients with primary Sj\u00f6gren's syndrome","volume":"12","author":"Verstappen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224842_bib4","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2023-224842_bib5","article-title":"Transcriptomic and network analysis of minor salivary glands of patients with primary Sj\u00f6gren's syndrome","volume":"11","author":"Oyelakin","year":"2020","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224842_bib6","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/art.39204","article-title":"Molecular subsetting of interferon pathways in Sj\u00f6gren's syndrome","volume":"67","author":"Hall","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib7","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/art.42238","article-title":"Symptom-based cluster analysis categorizes Sj\u00f6gren's disease subtypes: an international cohort study highlighting disease severity and treatment discordance","volume":"74","author":"McCoy","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard-2023-224503","article-title":"Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis","volume":"83","author":"Berry","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224842_bib9","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/clin.1994.1123","article-title":"Sj\u00f6gren's syndrome: autoimmune epithelitis","volume":"72","author":"Moutsopoulos","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1136\/ard-2023-224842_bib11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren's syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224842_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2478\/rir-2022-0017","article-title":"JAK\/STAT pathway targeting in primary Sj\u00f6gren syndrome","volume":"3","author":"Gandolfo","year":"2022","journal-title":"Rheumatol Immunol Res"},{"key":"10.1136\/ard-2023-224842_bib13","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/art.40589","article-title":"JAK-1 inhibition suppresses interferon-induced BAFF production in human salivary gland: potential therapeutic strategy for primary Sj\u00f6gren's syndrome","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.854183","article-title":"Aberrant signaling of immune cells in Sj\u00f6gren's syndrome patient subgroups upon interferon stimulation","volume":"13","author":"Sarkar","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224842_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90569-w","article-title":"Gene expression alterations in salivary gland epithelia of Sj\u00f6gren's syndrome patients are associated with clinical and histopathological manifestations","volume":"11","author":"Dela Cruz","year":"2021","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2023-224842_bib16","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/rheumatology\/keaa670","article-title":"Tofacitinib counteracts IL-6 overexpression induced by deficient Autophagy: implications in Sj\u00f6gren's syndrome","volume":"60","author":"Barrera","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224842_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"American college of rheumatology\/European league against rheumatism classification criteria for primary sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"10.1136\/ard-2023-224842_bib19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ebiom.2019.09.010","article-title":"Dual function of miR-1248 links interferon induction and calcium signaling defects in Sj\u00f6gren's syndrome","volume":"48","author":"Jang","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1136\/ard-2023-224842_bib20","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41591-021-01296-8","article-title":"SARS-Cov-2 infection of the oral cavity and saliva","volume":"27","author":"Huang","year":"2021","journal-title":"Nat Med"},{"key":"10.1136\/ard-2023-224842_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.699722","article-title":"Sclerosing sialadenitis is associated with salivary gland hypofunction and a unique gene expression profile in Sj\u00f6gren's syndrome","volume":"12","author":"Yin","year":"2021","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224842_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12859-021-04344-9","article-title":"Cellprofiler 4: improvements in speed, utility and usability","volume":"22","author":"Stirling","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"10.1136\/ard-2023-224842_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14755-5","article-title":"Assessment of variability in the somascan assay","volume":"7","author":"Candia","year":"2017","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2023-224842_bib24","author":"Salivary Gland Molecular Anatomy Project"},{"key":"10.1136\/ard-2023-224842_bib26","article-title":"Development of potential pharmacodynamic and diagnostic markers for anti-IFN-\u0391 monoclonal antibody trials in systemic lupus erythematosus","volume":"2009","author":"Yao","year":"2009","journal-title":"Hum Genomics Proteomics"},{"key":"10.1136\/ard-2023-224842_bib27","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/art.39607","article-title":"Distinct functions of autoantibodies against interferon in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatic diseases","volume":"68","author":"Gupta","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/ar1015","article-title":"Microarray analysis of gene expression in lupus","volume":"5","author":"Crow","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224842_bib29","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224842_bib30","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard-2023-224842_bib31","article-title":"Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus","volume":"10","author":"Smith","year":"2020","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2023-224842_bib32","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren's syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard-2023-224842_bib33","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1084\/jem.20020437","article-title":"The inducible Cxcr3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)\/Cxcl12","volume":"198","author":"Vanbervliet","year":"2003","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2023-224842_bib34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial-immune cell interplay in primary Sjogren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1249235","article-title":"Endothelial type I interferon response and brain diseases: identifying STING as a therapeutic target","volume":"11","author":"Duarte","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"10.1136\/ard-2023-224842_bib36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I Interferons in Sj\u00f6gren's syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2023-224842_bib37","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.tripleo.2008.09.015","article-title":"Association between IFN-alpha and primary Sjogren's syndrome","volume":"107","author":"Zheng","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1136\/ard-2023-224842_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ard-2023-224842_bib39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41584-021-00634-x","article-title":"Current and future therapies for primary Sj\u00f6gren syndrome","volume":"17","author":"Seror","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib40","first-page":"185","article-title":"Type I interferon signature in Sj\u00f6gren's syndrome: pathophysiological and clinical implications","volume":"37","author":"Marketos","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncprheum0173","article-title":"Mechanisms of disease: primary Sj\u00f6gren's syndrome and the type I interferon system","volume":"2","author":"Nordmark","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2023-224842_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren's syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat Commun"},{"issue":"Suppl 112","key":"10.1136\/ard-2023-224842_bib44","first-page":"31","article-title":"Increased expression of interferon-\u039b in minor salivary glands of patients with primary Sj\u00f6gren's syndrome and its Synergic effect with interferon-\u03b1 on salivary gland epithelial cells","volume":"36","author":"Ha","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2023-224842_bib45","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sj\u00f6gren's syndrome: a possible etiopathogenic mechanism","volume":"52","author":"B\u00e5ve","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224842_bib46","doi-asserted-by":"crossref","first-page":"17609","DOI":"10.1073\/pnas.1209724109","article-title":"Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases","volume":"109","author":"Hall","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard-2023-224842_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.coi.2018.05.014","article-title":"Crosstalk between type I and II Interferons in regulation of myeloid cell responses during bacterial infection","volume":"54","author":"Crisler","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/ard-2023-224842_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000361","article-title":"Functional crosstalk between type I and II interferon through the regulated expression of Stat1","volume":"8","author":"Gough","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1136\/ard-2023-224842_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II Interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224842_bib50","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in Cd14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224842_bib51","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10753-020-01322-w","article-title":"Inhibition of JAK-STAT signaling by baricitinib reduces interferon-\u0393-induced Cxcl10 production in human salivary gland ductal cells","volume":"44","author":"Aota","year":"2021","journal-title":"Inflammation"},{"key":"10.1136\/ard-2023-224842_bib52","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1093\/rheumatology\/keaa695","article-title":"Increased expression of Interleukin-21-inducible genes in minor salivary glands are associated with primary Sj\u00f6gren's syndrome disease characteristics","volume":"60","author":"Chen","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224842_bib53","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1002\/art.22176","article-title":"Overexpression of phosphorylated STAT-1Alpha in the labial salivary glands of patients with Sj\u00f6gren's syndrome","volume":"54","author":"Wakamatsu","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224842_bib54","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clim.2016.03.010","article-title":"Cytokine-induced stat1 activation is increased in patients with primary Sj\u00f6gren's syndrome","volume":"165","author":"Pertovaara","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1136\/ard-2023-224842_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002694","article-title":"Phosphorylated signal transducer and activator of transcription proteins 1 in salivary glandular tissue: an important histological marker for diagnosis of primary Sj\u00f6gren's syndrome","volume":"9","author":"Zheng","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-224842_bib56","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/cei.12377","article-title":"Dysregulation of the suppressor of cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the aetiopathogenesis of Sj\u00f6gren's syndrome","volume":"177","author":"Vartoukian","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard-2023-224842_bib57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaut.2012.05.019","article-title":"The T cell in Sjogren's syndrome: force majeure, not spectateur","volume":"39","author":"Singh","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2023-224842_bib58","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1126\/scisignal.290pe61","article-title":"Stat3 Revs up the powerhouse","volume":"2","author":"Reich","year":"2009","journal-title":"Sci Signal"},{"key":"10.1136\/ard-2023-224842_bib59","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fimmu.2019.00281","article-title":"Single cell based phosphorylation profiling identifies alterations in toll-like receptor 7 and 9 signaling in patients with primary Sj\u00f6gren's syndrome","volume":"10","author":"Davies","year":"2019","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224842_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.drup.2010.04.001","article-title":"Defining the role of the JAK-STAT pathway in head and neck and Thoracic malignancies: implications for future therapeutic approaches","volume":"13","author":"Lai","year":"2010","journal-title":"Drug Resist Updat"},{"key":"10.1136\/ard-2023-224842_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01448","article-title":"Fine-tuning of type I interferon response by Stat3","volume":"10","author":"Tsai","year":"2019","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224842_bib62","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus Kinases to Jakinibs: from basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 2","key":"10.1136\/ard-2023-224842_bib63","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224842_bib64","unstructured":"Annex I summary of product characteristics. 2017."},{"key":"10.1136\/ard-2023-224842_bib65","unstructured":"Xeljanz (tofacitinib) prescribing information. 2022."},{"key":"10.1136\/ard-2023-224842_bib66","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224842_bib67","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224842_bib68","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3B\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224842_bib69","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224842_bib70","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the Tyk2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1136\/ard-2023-224842_bib71","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1556\/EuJMI.2.2012.2.3","article-title":"Impact of enzymatic tissue disintegration on the level of surface molecule expression and immune cell function","volume":"2","author":"Autengruber","year":"2012","journal-title":"Eur J Microbiol Immunol (Bp)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T01:00:48Z","timestamp":1736038848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0003496724000268"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224842","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.16.23294130","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sj\u00f6gren's disease","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}